Get started
Work

1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer

Year: 2024
Type: review
Abstract: The 27-gene HER2DX test predicts pathological complete response (pCR) following neoadjuvant trastuzumab-based chemotherapy for HER2-positive (HER2+) breast cancer. Furthermore, HER2DX was associated with survival outcomes across individual studies using different treatment strategies. Here, we combine the existing data to evaluate the prognostic capacity of HER2DX to predict survival outcomes.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2024.103011
Authors: G. Villacampa Javierre, J. Cortés, J.M. Pérez García, A. Llombart Cussac, P. Tarantino, P.F. Conte, M. Mancino, V. Guarneri, M.V. Dieci, A. Waks, F. Brasó-Maristany, T. Pascual, G. Griguolo, P. Villagrasa Gonzalez, J. Parker, A. Vivancos, C.M. Perou, L. Pare Brunet, A. Prat, S.M. Tolaney
Institutions: Vall d'Hebron Institute of Oncology, MedSIR (Spain), Dana-Farber Cancer Institute, Istituto Oncologico Veneto, University of Padua, Harvard University, Fundació Clínic per a la Recerca Biomèdica, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic de Barcelona, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Vall d'Hebron Hospital Universitari
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,730
OpenAlex ID: W4397007960
FWCI: 0.322
Cites:
Cited by: 4
Related to: 10